PE20080424A1 - Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas - Google Patents

Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas

Info

Publication number
PE20080424A1
PE20080424A1 PE2007001088A PE2007001088A PE20080424A1 PE 20080424 A1 PE20080424 A1 PE 20080424A1 PE 2007001088 A PE2007001088 A PE 2007001088A PE 2007001088 A PE2007001088 A PE 2007001088A PE 20080424 A1 PE20080424 A1 PE 20080424A1
Authority
PE
Peru
Prior art keywords
maleate
trifluorometil
metoxy
quinolin
difluorophenyl
Prior art date
Application number
PE2007001088A
Other languages
English (en)
Inventor
Xiaoming Chen
Xiao Chen
Jianguo Yin
Xiaoyong Fu
David J Blythin
Rongze Kuang
Ho-Jane Shue
Scott Trzaska
Chee-Wah Tang
Vicenzo Liotta
Zaher Shabani
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38895795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080424(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20080424A1 publication Critical patent/PE20080424A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A FORMAS CRISTALINAS DE LAS SALES MALEATO, TOSILATO, FUMARATO Y OXALATO DEL COMPUESTO 5-(1(S)-AMINO-2-HIDROXIETIL)-N-[(2,4-DIFLUOROFENIL)-METIL]-2-[8-METOXI-2-(TRIFLUOROMETIL)-5-QUINOLIN]-4-OXAZOLCARBOXAMIDA DE FORMULA (I), EN DONDE LA SAL MALEATO TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVO EXPRESADO EN 2O DE 6,5; 7,5; 21,2; 27,2; ENTRE OTROS; LA SAL TOSILATO TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVO EXPRESADO EN 2O DE 5,2; 12,5; 20,0; 26,3; ENTRE OTROS; LA SAL FUMARATO TIENE UN PATRON DE DIFRACCION DE RAYOS X DE POLVO EXPRESADO EN 2O DE 8,0; 19,9; 22,5; 25,6; ENTRE OTROS. SE REFIERE TAMBIEN A PROCEDIMIENTOS DE PREPARACION DE DICHAS FORMAS CRISTALINAS. DICHO COMPUESTO ES UN INHIBIDOR DE LA FOSFODIESTERASA 4 (PDE-4) SIENDO UTIL EN EL TRATAMIENTO DE ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
PE2007001088A 2006-08-14 2007-08-14 Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas PE20080424A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83766106P 2006-08-14 2006-08-14

Publications (1)

Publication Number Publication Date
PE20080424A1 true PE20080424A1 (es) 2008-04-28

Family

ID=38895795

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001088A PE20080424A1 (es) 2006-08-14 2007-08-14 Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas

Country Status (11)

Country Link
US (1) US7956189B2 (es)
EP (1) EP2069337A1 (es)
JP (3) JP2010500406A (es)
CN (1) CN101522671A (es)
AR (1) AR062373A1 (es)
CA (1) CA2660703A1 (es)
CL (1) CL2007002366A1 (es)
MX (1) MX2009001770A (es)
PE (1) PE20080424A1 (es)
TW (1) TW200819446A (es)
WO (1) WO2008021271A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
EP2875020B1 (en) * 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
EP3833660A4 (en) * 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565599C (en) * 2004-05-18 2012-07-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors

Also Published As

Publication number Publication date
JP2012176989A (ja) 2012-09-13
CL2007002366A1 (es) 2008-03-14
EP2069337A1 (en) 2009-06-17
US7956189B2 (en) 2011-06-07
AR062373A1 (es) 2008-11-05
WO2008021271A1 (en) 2008-02-21
US20080108818A1 (en) 2008-05-08
CN101522671A (zh) 2009-09-02
TW200819446A (en) 2008-05-01
JP2010500406A (ja) 2010-01-07
CA2660703A1 (en) 2008-02-21
JP2013032394A (ja) 2013-02-14
MX2009001770A (es) 2009-02-25

Similar Documents

Publication Publication Date Title
PE20080424A1 (es) Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas
PE20141148A1 (es) Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
PE20142355A1 (es) 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)ureas como inhibidores de proteinas cinasas activadas por mitogeno p38
TR201904655T4 (tr) Piridilaminoasetik asit bileşiği.
MA35608B1 (fr) 3,5-diamino-6-chloro-n-(n-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)-amino)éthoxy)phényl)butyl)carbamimidoyl)pyrazine-2-carboxamide
PE20061347A1 (es) Forma cristalina de la sal de difosfato del acido bifenil-2-ilcarbamico 1-(2-{[4-(4-carbamoilpiperidin-1-ilmetil)benzoil]metilamino}etil)piperidin-4-il ester
AR062927A1 (es) 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2008513510A5 (es)
RU2010128512A (ru) Гетероциклические ингибиторы мек и способы их применения
ECSP077356A (es) Forma termodinámicamente estable de una sal tosilato
ECSP088217A (es) Formas de cristal delta y épsilon de mesilato de imatinib
GEP201706735B (en) Kinase inhibitors
PE20121337A1 (es) Forma cristalina y amorfa de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
PE20091213A1 (es) Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico
RU2019100065A (ru) Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR
PE20080949A1 (es) Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
AR058109A1 (es) Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
JP2008542390A5 (es)
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
JP2012500205A5 (es)
RU2010108505A (ru) Применение производных пурина для изготовления лекарственного препарата
AR051213A1 (es) 1-(2-(4-bencil-4-hidroxi-piperidin-1-il)-etil)-3-(2-metil-quinolin-4-il)-urea como una sal sulfato cristalina

Legal Events

Date Code Title Description
FC Refusal